Show simple item record

dc.contributor.authorStub, Trine
dc.contributor.authorHervik, Jill Brook
dc.date.accessioned2017-03-09T14:36:32Z
dc.date.available2017-03-09T14:36:32Z
dc.date.issued2016-10-05
dc.description.abstractPurpose: To access frequency and severity of adverse effects (AE) of non-hormonal drugs (NHD) for hot flashes in breast cancer survivors compared to controls and analyze adverse-effect risk by reviewing published randomized trials. <p>Methods: Cochrane Central Register for Controlled Trials, Embase, Medline, PsycINFO and PubMed databases were searched. Trials were included where participants were survivors of breast cancer suffering from hot flashes, treatment included self-administered venlafaxine, gabapentin or clonidine, and AE were reported. AE frequency and severity were graded. A meta-analysis of ten trials with sub-group analyses was conducted. <p>Results: Forty-nine studies were identified, and 12 were included. A total of 1467 participants experienced 772 adverse effects, 81 % (n = 627) in the treatment group and 19 % (n = 145) in the control group. Sixty-seven percent of AE was graded as mild and 33 % as moderate. The frequency of AE for NHD was overall significant compared to placebo. Sub-group analysis indicated that AE frequency and severity increased at higher doses of venlafaxine and gabapentin compared to placebo. <p>Conclusion: The odds for experiencing AE was significantly higher in patients randomized to high-dose NHD than those randomized to controls, including placebo, lowdose medication and acupuncture. These therapies should be considered as a potential treatment alternative.en_US
dc.descriptionPublished version. Source at <a href=http://dx.doi.org/10.1007/s10549-016-4002-x> http://dx.doi.org/10.1007/s10549-016-4002-x </a>en_US
dc.identifier.citationHervik, J. B., Stub, T.: Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis. Breast Cancer Research and Treatment. 2016;160(2):223-236en_US
dc.identifier.issn0167-6806
dc.identifier.issn1573-7217
dc.identifier.otherFRIDAID 1390335
dc.identifier.other10.1007/s10549-016-4002-x
dc.identifier.urihttps://hdl.handle.net/10037/10528
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.relation.journalBreast Cancer Research and Treatment
dc.rights.accessRightsopenAccessen_US
dc.subject.hrcsKreft: Legemidler
dc.subject.hrcsCancer : Pharmaceuticals
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728en_US
dc.subjectAdverse effectsen_US
dc.subjectNon-hormonal drugsen_US
dc.subjectBreast canceren_US
dc.subjectHot flashesen_US
dc.titleAdverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysisen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record